BACKGROUNDMechanical ventilation can increase the risk of VAP 7 -21 times and 10% -25% of patients undergoing mechanical ventilation develop pneumonia. The aetiological agents of VAP vary with different patient populations and types of ICUs. Prompt administration of appropriate antibiotics seems to be the only intervention that alters outcome once the diagnosis is established. MATERIALS AND METHODSThis is a descriptive study with seventy-four non-repetitive endotracheal aspirate from patients who were on mechanical ventilation for more than 48 hrs. and in whom ventilator associated pneumonia was suspected using modified CPIS score and quantitative culture was confirmed using modified two-fold dilution scheme. Kirby-Bauer disk diffusion method was adopted for antimicrobial susceptibility testing. RESULTSThe most common isolate was pseudomonas aeruginosa (27%) followed by Acinetobacter spp. (20.3%), Klebsiella spp. (16.2%) and E. coli (12%). Among gram positive bacteria in our study, only Staphylococcus aureus (9.5%) was isolated. Amikacin and levofloxacin were found to be better against non-fermenters; 10% were carbapenemase producers, MDR isolates were observed in enterobacteriaceae members. MRSA was found in 28.6%. CONCLUSIONIn conclusion, the incidence of VAP and the prevalence of multidrug resistant microorganisms were quite high in our ICU setup. A local surveillance program at each centre is essential, as the knowledge of local resistant patterns is vital for selecting the appropriate agents for treating infections. BACKGROUNDVentilator-associated pneumonia (VAP) is defined as pneumonia occurring more than 48 hours after the initiation of endotracheal intubation and mechanical ventilation (MV) including pneumonia developing even after extubation. 1 Mechanical ventilation can increase the risk of VAP 7 -21 times and 10% -25% of patients undergoing mechanical ventilation develop pneumonia. 2 It results in high mortality and morbidity, prolonged lengths of hospitalisation and also increased cost of hospitalisation. The mortality rates for VAP range from 20% to 75% according to the study population. 3 Accurate data on aetiologic agents and the epidemiology of VAP are limited by the lack of a 'gold standard' for diagnosis. However, regardless of the diagnostic technique used, there have been dramatic variations in the distribution of pathogens and drug resistance patterns. Because early and
Urinary tract infections (UTIs) are among the most prevalent nosocomial and community-acquired bacterial diseases in humans, with E.coli being the most typical pathogen isolated. To detect the prevalence of virulence factors like haemolysin, haemagglutination of human erythrocytes with its effect of D-mannose, and cell surface hydrophobicity, the antibiotic sensitivity pattern and ESBL production in urinary isolates of E.coli obtained from clinical samples. We included the E.coli isolates obtained from a midstream urine sample for the study. Virulence factors like haemolysin, hemagglutination and salt aggregation were detected as per standard protocols. Antibiotic sensitivity testing was performed by the Kirby Bauer disc diffusion method. Extended-spectrum beta-lactamase (ESBL) production was seen by the combined disc diffusion method on Muller Hinton agar as per CLSI guidelines. A total of 103 E.coli isolates were tested, and among them, 24(23.30%) produced haemolysin, 65(63.10%) produced hemagglutination and 38(36.89%) had salt aggregation properties. Most isolates obtained were resistant to beta-lactam antibiotics but showed high sensitivity towards antibiotics like chloramphenicol, meropenem, amikacin, imipenem and nitrofurantoin. Around 48% of them were ESBL producers. The common virulence factors associated with UTI were P-fimbriae (MRHA), haemolysin production, cell surface hydrophobicity and type-1 fimbriae. Because of the emerging drug resistance among UPEC, therapy should be advocated as far as possible after obtaining the culture and sensitivity results to determine exact aetiology and susceptibility patterns. The sensitivity to nitrofurantoin is very high, suggesting that antibiotic recycling will help clinicians treat UPEC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.